Scratching the surface: unmet needs in psoriasis
Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase
Psoriasis is a skin condition but its impact goes much further than skin-deep. The late US novelist John Updike, who had psoriasis from the age of six, talked about being ‘At War with my Skin’.
The martial metaphor is no exaggeration. Updike hesitated to use the term ‘disease’ for something “not contagious, painful, or debilitating”. Yet his psoriasis still had “the volatility of a disease, the sense of another presence co-occupying your body and singling you out from the happy herds of healthy, normal, mankind”.
Atopic Dermatitis — Going Beyond the Pill
Published in Pharma Exec April 2018 by Mariel Metcalfe
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more.
Patient centricity: Reality or rhetoric?
Everybody is talking about patient centricity, but what does it mean for those involved in market research, insights and business intelligence?
The term has certainly begun to filter through to the pharmaceutical market research industry. It was a hot topic at EphMRA conference in 2017, with a number of presentations from agencies, including some innovative new research offerings.
Living with NASH: An Unexpected Diagnosis
Published in eyeforpharma November 2017 by Mariel Metcalfe
With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs. As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol.
Research Partnership publishes 2017 Living with NASH report
Healthcare market research and consultancy specialist Research Partnership has published a new Living with Non-alcoholic Steatohepatitis report for 2017. Living with Non-alcoholic Steatohepatitis (NASH) is a quantitative US study conducted online amongst patients. The report consists of 45-minute online interviews with 108 NASH or NAFLD patients; a small number of qualitative interviews were also conducted.